As the armamentarium of treatment for rheumatoid arthritis (RA) grows, identifying the right patients for the right treatment, measuring response to therapy, sequencing therapies, and mitigating healthcare resource use and associated costs all need to be addressed. Appropriate real-world data may generate the necessary evidence to answer these evolving questions. Claims-based analyses and electronic health record systems that are not specific to rheumatology cannot provide the depth of data required to unravel the complexity of treatment decision-making and clinical outcomes in RA. In this upcoming webinar from the Real-World Evidence & Insights team at Cardinal Health, Dr. Bruce Feinberg moderates a panel on alternative approaches to real-world evidence generation in RA. In a series of case study evaluations, the panel will explore:
o Identifying clinically meaningful subgroups of RA patients
o Measuring disease activity and response to treatment
o Assessing patient perspectives
o Supporting key stakeholders to inform healthcare decision-making
Biopharma manufacturers focused in medical affairs, real-world evidence, outcomes research and regulatory affairs are encouraged to attend.